Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study

Overview of attention for article published in BMC Cancer, May 2022

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 4 X posts from 3 X users, with an upper bound of 1,222 followers.

Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study. https://t.co/ZyrWXYYjAj https://t.co/J8itWEJrVx

Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study https://t.co/rrpjdjXBot

New article: Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study https://t.co/poIT72oRSv #livercancer #oncology https://t.co/TRvbhxaFpW

New article: Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study https://t.co/3SX1JD86by #melanoma #oncology https://t.co/wZK35aPuOz

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.